Magnolol ameliorates lipopolysaccharide-induced acute lung injury in rats through PPAR-γ-dependent inhibition of NF-kB activation

Int Immunopharmacol. 2015 Sep;28(1):270-8. doi: 10.1016/j.intimp.2015.05.051. Epub 2015 Jun 10.

Abstract

Acute lung injury (ALI) has a high morbidity and mortality rate due to the serious inflammation and edema occurred in lung. Magnolol extracted from Magnolia officinalis, has been reported to exhibit anti-inflammatory, and antioxidant activities. Peroxisome proliferator-activated receptors (PPARs) are known to exert a cytoprotective effect against cellular inflammatory stress and oxidative injury. The aim of this study was to explore the involvement of PPAR-γ in the beneficial effect of magnolol in lipopolysaccharide (LPS)-induced ALI. We found that treatment with magnolol greatly improved the pathological features of ALI evidenced by reduction of lung edema, polymorphonuclear neutrophil infiltration, ROS production, the levels of pro-inflammatory cytokines in bronchoalveolar lavage fluid (BALF), the expression of iNOS and COX-2, and NF-κB activation in lungs exposed to LPS. Importantly, magnolol is capable of increasing the PPAR-γ expression and activity in lungs of ALI. However, blocking PPAR-γ activity with GW9662 markedly abolished the protective and anti-inflammatory effects of magnolol. Taken together, the present study provides a novel mechanism accounting for the protective effect of magnolol in LPS-induced ALI is at least partly attributed to induction of PPAR-γ in lungs, and in turn suppressing NF-κB-related inflammatory responses.

Keywords: Acute lung injury; Lipopolysaccharide; Magnolol; Peroxisome proliferator-activated receptor gamma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Lung Injury / chemically induced*
  • Acute Lung Injury / pathology
  • Acute Lung Injury / prevention & control*
  • Anilides / pharmacology
  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Biphenyl Compounds / antagonists & inhibitors
  • Biphenyl Compounds / therapeutic use*
  • Bronchoalveolar Lavage Fluid / chemistry
  • Cytokines / analysis
  • Cytokines / metabolism
  • Lignans / antagonists & inhibitors
  • Lignans / therapeutic use*
  • Lipopolysaccharides*
  • Male
  • NF-kappa B / antagonists & inhibitors*
  • Neutrophil Infiltration
  • Oxidative Stress / drug effects
  • PPAR gamma / antagonists & inhibitors*
  • Peroxidase / metabolism
  • Pulmonary Edema / pathology
  • Pulmonary Edema / prevention & control
  • Rats
  • Rats, Sprague-Dawley
  • Reactive Oxygen Species / metabolism

Substances

  • 2-chloro-5-nitrobenzanilide
  • Anilides
  • Anti-Inflammatory Agents, Non-Steroidal
  • Biphenyl Compounds
  • Cytokines
  • Lignans
  • Lipopolysaccharides
  • NF-kappa B
  • PPAR gamma
  • Reactive Oxygen Species
  • magnolol
  • Peroxidase